Equities analysts expect that SomaLogic, Inc. (NASDAQ:SLGC – Get Rating) will post $23.30 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for SomaLogic’s earnings. The lowest sales estimate is $23.00 million and the highest is $23.60 million. The company is scheduled to report its next quarterly earnings report on Monday, January 1st.
On average, analysts expect that SomaLogic will report full-year sales of $106.20 million for the current year, with estimates ranging from $105.00 million to $107.40 million. For the next year, analysts forecast that the firm will post sales of $150.80 million, with estimates ranging from $145.00 million to $156.60 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that follow SomaLogic.
SomaLogic (NASDAQ:SLGC – Get Rating) last posted its quarterly earnings results on Tuesday, March 29th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.01).
A number of institutional investors and hedge funds have recently modified their holdings of the business. Wolverine Asset Management LLC purchased a new stake in shares of SomaLogic during the 4th quarter valued at $36,000. PNC Financial Services Group Inc. purchased a new stake in shares of SomaLogic during the 3rd quarter valued at $37,000. UBS Group AG purchased a new stake in shares of SomaLogic during the 3rd quarter valued at $58,000. Penserra Capital Management LLC purchased a new stake in shares of SomaLogic during the 4th quarter valued at $98,000. Finally, Citadel Advisors LLC purchased a new stake in shares of SomaLogic during the 3rd quarter valued at $129,000. Institutional investors own 44.55% of the company’s stock.
Shares of SLGC stock traded up $0.10 during midday trading on Wednesday, reaching $6.88. 1,257,626 shares of the company traded hands, compared to its average volume of 1,082,023. The firm’s 50 day simple moving average is $8.35 and its two-hundred day simple moving average is $10.26. SomaLogic has a 1-year low of $6.67 and a 1-year high of $14.72.
About SomaLogic (Get Rating)
SomaLogic, Inc operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples.
- Get a free copy of the StockNews.com research report on SomaLogic (SLGC)
- OrganiGram’s Turnaround Begins To Blossom
- Three Dividend Stocks With Growth Potential
- Exelon Stock Still Has Extraordinary Upside
- Ross Stores On The Verge Of Major Rally
- Greenbrier Companies Stock has Green in its Future
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for SomaLogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SomaLogic and related companies with MarketBeat.com's FREE daily email newsletter.